Number of Substitute Targets. Notwithstanding anything to the contrary contained in this Agreement, in no event will AstraZeneca have the right to designate more than [***] Substitute Targets under this Section 3.3.7; provided that no more than [***] of such [***] Substitute Targets can be substituted in for an Oncology Target that has reached [***] status.
Appears in 2 contracts
Sources: Collaboration, License and Development Agreement (Ionis Pharmaceuticals Inc), Collaboration, License and Development Agreement (Isis Pharmaceuticals Inc)